Search Results - "Mamidi, N V S Rao"

Pharmacokinetics, efficacy and toxicity of different pegylated liposomal doxorubicin formulations in preclinical models: is a conventional bioequivalence approach sufficient to ensure therapeutic equivalence of pegylated liposomal doxorubicin products? by Mamidi, Rao N. V. S., Weng, Steve, Stellar, Susan, Wang, Charles, Yu, Ning, Huang, Tony, Tonelli, Alfred P., Kelley, Michael F., Angiuoli, Anthony, Fung, Man-Cheong

“…Purpose To examine whether a conventional bioequivalence approach is sufficient to ensure the therapeutic equivalence of liposomal products, the…”
Get full text

Niraparib with androgen receptor-axis-targeted therapy in patients with metastatic castration-resistant prostate cancer: safety and pharmacokinetic results from a phase 1b study (BEDIVERE) by Saad, Fred, Chi, Kim N., Shore, Neal D., Graff, Julie N., Posadas, Edwin M., Lattouf, Jean-Baptiste, Espina, Byron M., Zhu, Eugene, Yu, Alex, Hazra, Anasuya, De Meulder, Marc, Mamidi, Rao N. V. S., Bradic, Branislav, Francis, Peter, Hayreh, Vinny, Rezazadeh Kalebasty, Arash

“…Purpose To assess the safety and pharmacokinetics and determine the recommended phase 2 dose (RP2D) of niraparib with apalutamide or abiraterone acetate plus…”
Get full text

In vitro and physiologically‐based pharmacokinetic based assessment of drug–drug interaction potential of canagliflozin by Mamidi, Rao N. V. S., Dallas, Shannon, Sensenhauser, Carlo, Lim, Heng Keang, Scheers, Ellen, Verboven, Peter, Cuyckens, Filip, Leclercq, Laurent, Evans, David C., Kelley, Michael F., Johnson, Mark D., Snoeys, Jan

“…Aims Canagliflozin is a recently approved drug for use in the treatment of type 2 diabetes. The potential for canagliflozin to cause clinical drug–drug…”
Get full text

Metabolism and Excretion of RWJ-333369 [1,2-Ethanediol, 1-(2-Chlorophenyl)-, 2-carbamate, (S)-] in Mice, Rats, Rabbits, and Dogs by MAMIDI, Rao N. V. S, MANNENS, Geert, ANNAERT, Pieter, HENDRICKX, Jan, GORIS, Ivo, BOCKX, Mark, JANSSEN, Cor G. M, KAO, Mark, KELLEY, Michael F, MEULDERMANS, Willem

“…The in vivo metabolism and excretion of RWJ-333369 [1,2-ethanediol, 1-(2-chlorophenyl)-, 2-carbamate, ( S )-], a novel neuromodulator, were investigated in…”
Get full text

Prediction of the drug–drug interaction potential of the α1‐acid glycoprotein bound, CYP3A4/CYP2C9 metabolized oncology drug, erdafitinib by De Zwart, Loeckie, Snoeys, Jan, Jacobs, Frank, Li, Lilian Y., Poggesi, Italo, Verboven, Peter, Goris, Ivo, Scheers, Ellen, Wynant, Inneke, Monshouwer, Mario, Mamidi, Rao N. V. S.

“…Erdafitinib is a potent oral pan‐fibroblast growth factor receptor inhibitor being developed as oncology drug for patients with alterations in the fibroblast…”
Get full text

De-risking bio-therapeutics for possible drug interactions using cryopreserved human hepatocytes by Dallas, Shannon, Sensenhauser, Carlo, Batheja, Ameesha, Singer, Monica, Markowska, Maria, Zakszewski, Cindy, Mamidi, Rao N V S, McMillia, Michael, Han, Chao, Zhou, Honghui, Silva, Jose

“…Inflammatory diseases such as rheumatoid arthritis and psoriasis are characterized by increases in circulating cytokines, which play an important role in…”
Get more information

Tissue distribution and depletion kinetics of bortezomib and bortezomib-related radioactivity in male rats after single and repeated intravenous injection of 14C-bortezomib by HEMERYCK, Alex, GEERTS, Rita, DE COSTER, Roland, MONBALIU, Johan, HASSIER, Stephan, VERHAEGHE, Tom, DIELS, Luc, VERLUYTEN, Willy, VAN BEIJSTERVELDT, Ludy, MAMIDI, Rao N. V. S, JANSSEN, Cor

“…The body distribution of total radioactivity (TR) and bortezomib was investigated in male Sprague-Dawley rats after single and repeated i.v. (bolus)…”
Get full text

In vitro metabolism of canagliflozin in human liver, kidney, intestine microsomes, and recombinant uridine diphosphate glucuronosyltransferases (UGT) and the effect of genetic variability of UGT enzymes on the pharmacokinetics of canagliflozin in humans by Francke, Stephan, Mamidi, Rao N. V. S., Solanki, Bhavna, Scheers, Ellen, Jadwin, Andrew, Favis, Reyna, Devineni, Damayanthi

“…O‐glucuronidation is the major metabolic elimination pathway for canagliflozin. The objective was to identify enzymes and tissues involved in the formation of…”
Get full text

Synthesis of Conformationally Constrained Analogues of Linezolid:  Structure−Activity Relationship (SAR) Studies on Selected Novel Tricyclic Oxazolidinones by Selvakumar, Natesan, Srinivas, Deekonda, Khera, Manoj Kumar, Kumar, Magadi Sitaram, Mamidi, Rao N. V. S, Sarnaik, Hemanth, Charavaryamath, Chandrashekar, Rao, Bonthu Srinivasa, Raheem, Mohammed A, Das, Jagattaran, Iqbal, Javed, Rajagopalan, Ramanujam

“…In an effort to discover potent antibacterials based on the entropically favored “bioactive conformation” approach, we have designed and synthesized a series…”
Get full text

Synthesis and Cyclooxygenase-2 Inhibiting Property of 1,5-Diarylpyrazoles with Substituted Benzenesulfonamide Moiety as Pharmacophore:  Preparation of Sodium Salt for Injectable Formulation by Pal, Manojit, Madan, Manjula, Padakanti, Srinivas, Pattabiraman, Vijaya R, Kalleda, Srinivas, Vanguri, Akhila, Mullangi, Ramesh, Rao Mamidi, N. V. S, Casturi, Seshagiri R, Malde, Alpeshkumar, Gopalakrishnan, B, Yeleswarapu, Koteswar R

“…A series of 1,5-diarylpyrazoles having a substituted benzenesulfonamide moiety as pharmacophore was synthesized and evaluated for cyclooxygenase (COX-1/COX-2)…”
Get full text

Niraparib Shows Superior Tissue Distribution and Efficacy in a Prostate Cancer Bone Metastasis Model Compared with Other PARP Inhibitors by Snyder, Linda A., Damle, Rajendra, Patel, Shefali, Bohrer, Jared, Fiorella, Anna, Driscoll, Jenny, Hawkins, Rebecca, Stratton, Christopher F., Manning, Carol D., Tatikola, Kanaka, Tryputsen, Volha, Packman, Kathryn, Mamidi, Rao N.V.S.

“…Patients with prostate cancer whose tumors bear deleterious mutations in DNA-repair pathways often respond to PARP inhibitors. Studies were conducted to…”
Get full text

Metabolism and disposition in rats, dogs, and humans of erdafitinib, an orally administered potent pan-fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitor by Scheers, Ellen, Borgmans, Carine, Keung, Chi, Bohets, Hilde, Wynant, Inneke, Poggesi, Italo, Cuyckens, Filip, Leclercq, Laurent, Mamidi, Rao N. V. S.

“…This article describes in vivo biotransformation and disposition of erdafitinib following single oral dose of 3 H-erdafitinib and 14 C-erdafitinib to intact…”
Get full text

Metabolism and excretion of canagliflozin in mice, rats, dogs, and humans by Mamidi, Rao N V S, Cuyckens, Filip, Chen, Jie, Scheers, Ellen, Kalamaridis, Dennis, Lin, Ronghui, Silva, Jose, Sha, Sue, Evans, David C, Kelley, Michael F, Devineni, Damayanthi, Johnson, Mark D, Lim, Heng Keang

“…Canagliflozin is an oral antihyperglycemic agent used for the treatment of type 2 diabetes mellitus. It blocks the reabsorption of glucose in the proximal…”
Get full text

Carcinogenicity in rats of the SGLT2 inhibitor canagliflozin by De Jonghe, Sandra, Proctor, Jim, Vinken, Petra, Feyen, Bianca, Wynant, Inneke, Marien, Dirk, Geys, Helena, Mamidi, Rao N.V.S., Johnson, Mark D.

“…•Canagliflozin, an SGLT2 inhibitor for treatment of diabetes, caused tumors in rats.•Leydig cell tumors were attributed to increased luteinizing…”
Get full text

Effect of Fluconazole and Itraconazole on the Pharmacokinetics of Erdafitinib in Healthy Adults: A Randomized, Open-Label, Drug–Drug Interaction Study by Poggesi, Italo, Li, Lilian Y., Jiao, James, Hellemans, Peter, Rasschaert, Freya, de Zwart, Loeckie, Snoeys, Jan, De Meulder, Marc, Mamidi, Rao N. V. S., Ouellet, Daniele

“…Background and Objectives Erdafitinib, an oral selective pan-fibroblast growth factor receptor (FGFR) kinase inhibitor, is primarily metabolized by cytochrome…”
Get full text

Substituent activity relationship studies on new azolo benzoxazepinyl oxazolidinones by Das, Jagattaran, Sitaram Kumar, M., Subrahmanyam, D., Sastry, T.V.R.S., Prasad Narasimhulu, C., Laxman Rao, C.V., Kannan, M., Roshaiah, M., Awasthi, Riti, Patil, Santosh N., Sarnaik, H.M., Rao Mamidi, N.V.S., Selvakumar, N., Iqbal, Javed

“…The synthesis of a series of tricyclic oxazolidinones is disclosed. SAR studies on these novel compounds and evaluation of a lead compound are reported. In an…”
Get full text

Renal tubular and adrenal medullary tumors in the 2-year rat study with canagliflozin confirmed to be secondary to carbohydrate (glucose) malabsorption in the 15-month mechanistic rat study by De Jonghe, Sandra, Johnson, Mark D., Mamidi, Rao N.V.S., Vinken, Petra, Feyen, Bianca, Lammens, Godelieve, Proctor, Jim

“…During preclinical development of canagliflozin, an SGLT2 inhibitor, treatment-related pheochromocytomas, renal tubular tumors (RTT), and testicular Leydig…”
Get full text

2-hydroxymethyl-4-[5-(4-methoxyphenyl)-3-trifluoromethyl-1H-1-pyrazolyl]-1-benzenesulfonamide (DRF-4367): an orally active COX-2 inhibitor identified through pharmacophoric modulation by Singh, Sunil Kumar, Vobbalareddy, Saibaba, Kalleda, Srinivasa Rao, Rajjak, Shaikh Abdul, Casturi, Seshagiri Rao, Datla, Srinivasa Raju, Mamidi, Rao N V S, Mullangi, Ramesh, Bhamidipati, Ravikanth, Ramanujam, Rajagopalan, Akella, Venkateswarlu, Yeleswarapu, Koteswar Rao

“…Analogs of 1,5-diarylpyrazoles with a novel pharmacophore at N1 were designed, synthesized and evaluated for the in-vitro cyclooxygenase (COX-1/COX-2)…”
Get more information

Novel Antidiabetic and Hypolipidemic Agents. 5. Hydroxyl versus Benzyloxy Containing Chroman Derivatives by Reddy, K. Anji, Lohray, B. B, Bhushan, V, Reddy, A. Sekar, Mamidi, N. V. S. Rao, Reddy, P. Papi, Saibaba, V, Reddy, N. Jaipal, Suryaprakash, A, Misra, Parimal, Vikramadithyan, Reeba K, Rajagopalan, R

“…Several thiazolidinediones having chroman moieties were synthesized and evaluated for their euglycemic and hypolipidemic activities. Some of the analogues…”
Get full text

Safety, Tolerability, and Pharmacokinetics of a Capsule Formulation of DRF-1042, a Novel Camptothecin Analog, in Refractory Cancer Patients in a Bridging Phase I Study by Chatterjee, Arani, Digumarti, Raghunadharao, Katneni, Kasiram, Upreti, Vijay V., Mamidi, Rao N. V. S., Mullangi, Ramesh, Surath, Anjna, Srinivas, Maddali L., Uppalapati, Srihari, Jiwatani, Sangeeta, Srinivas, Nuggehally R.

“…The purpose of this bridging phase I study was to characterize the toxicity, pharmacokinetics, and antitumor effects of a capsule formulation of DRF‐1042, a…”
Get full text